| Literature DB >> 34823729 |
Thomas Hickey1, Audrey Abelleira2, Gregory Acampora3, William C Becker4, Caroline G Falker2, Mitchell Nazario5, Melissa B Weimer6.
Abstract
Buprenorphine formulations (including buprenorphine/naloxone) are effective treatments of pain and opioid use disorder (OUD). Historically, perioperative management of patients prescribed buprenorphine involved abstinence from buprenorphine sufficient to allow for unrestricted mu-opioid receptor availability to full agonist opioid (FAO) treatment. Evidence is mounting that a multimodal analgesic strategy, including simultaneous administration of buprenorphine and FAO, nonopioid adjuncts such as acetaminophen and nonsteroidal anti-inflammatory drugs, and regional anesthesia, is a safe and effective perioperative strategy for the patient prescribed long-term buprenorphine treatment of OUD. This strategy will likely simplify management and more seamlessly provide continuous buprenorphine treatment of OUD after hospital discharge.Entities:
Keywords: Analgesia; Buprenorphine; Opioid-related disorders; Pain; Partial opioid agonists; Postoperative
Mesh:
Substances:
Year: 2022 PMID: 34823729 DOI: 10.1016/j.mcna.2021.09.001
Source DB: PubMed Journal: Med Clin North Am ISSN: 0025-7125 Impact factor: 5.456